AVGN Avigen (MM)

ALAMEDA, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Avigen, Inc. (NASDAQ:AVGN) a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions announced that it will be discussing its fourth quarter and full year 2005 results in a conference call at 9:00 am (Eastern time) on Thursday, February 16th, 2006. Ken Chahine, chief executive officer, and Michael Coffee, Chief Business Officer, can be heard by dialing 866-713-8562 (tollfree) in the U.S. or +1-617-597-5310 (toll) elsewhere. Conference ID 19679959 This call is also being webcast live and can be accessed at Avigen's Web site at http://www.avigen.com/. For those who cannot listen to the live broadcast, a replay will be available shortly after the conference call on the link on the company's website http://www.avigen.com/ or by dialing 888-286-8010 (tollfree) in the U.S. or +1-617-801-6888 (toll) elsewhere, and entering the access code 60707431. For press releases and other corporate information, visit our website at http://www.avigen.com/. DATASOURCE: Avigen, Inc. CONTACT: Michael Coffee, Chief Business Officer of Avigen, Inc., +1-510-748-7372, or fax, +1-510-748-7384, or Web site: http://www.avigen.com/

Copyright